Nordea Investment Management AB Has $7.95 Million Stake in Charles River Laboratories Intl. Inc (NYSE:CRL)

Nordea Investment Management AB lessened its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 70,231 shares of the medical research company’s stock after selling 4,410 shares during the period. Nordea Investment Management AB owned 0.15% of Charles River Laboratories Intl. worth $7,948,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fort L.P. acquired a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth about $27,000. Riverview Trust Co acquired a new stake in Charles River Laboratories Intl. in the 4th quarter valued at about $30,000. Kwmg LLC raised its holdings in Charles River Laboratories Intl. by 32.4% in the 4th quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 105 shares during the last quarter. Captrust Financial Advisors raised its holdings in Charles River Laboratories Intl. by 101.3% in the 4th quarter. Captrust Financial Advisors now owns 612 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 308 shares during the last quarter. Finally, Csenge Advisory Group acquired a new stake in Charles River Laboratories Intl. in the 3rd quarter valued at about $91,000. Hedge funds and other institutional investors own 94.10% of the company’s stock.

In other news, Chairman James C. Foster sold 513 shares of the firm’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $142.49, for a total value of $73,097.37. Following the sale, the chairman now directly owns 300,777 shares in the company, valued at approximately $42,857,714.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 5,522 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $137.61, for a total transaction of $759,882.42. Following the completion of the sale, the executive vice president now owns 16,325 shares in the company, valued at $2,246,483.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,428 shares of company stock worth $4,597,693. 2.10% of the stock is owned by company insiders.

Several analysts have recently weighed in on CRL shares. SunTrust Banks increased their price target on shares of Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research note on Thursday, February 14th. Jefferies Financial Group reissued a “buy” rating and issued a $162.00 price target on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. Barclays reissued a “hold” rating and issued a $135.00 price target on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. KeyCorp increased their price target on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research note on Monday, March 11th. Finally, ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $144.54.

Charles River Laboratories Intl. stock traded up $0.96 during mid-day trading on Wednesday, reaching $137.00. 367,800 shares of the company’s stock were exchanged, compared to its average volume of 395,871. The firm has a market cap of $6.53 billion, a PE ratio of 22.72, a price-to-earnings-growth ratio of 1.74 and a beta of 1.03. Charles River Laboratories Intl. Inc has a twelve month low of $102.96 and a twelve month high of $149.07. The company has a quick ratio of 1.38, a current ratio of 1.61 and a debt-to-equity ratio of 1.24.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Wednesday, February 13th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.10. The company had revenue of $605.53 million for the quarter, compared to analyst estimates of $589.86 million. Charles River Laboratories Intl. had a net margin of 9.99% and a return on equity of 24.09%. The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.40 EPS. On average, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.48 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Nordea Investment Management AB Has $7.95 Million Stake in Charles River Laboratories Intl. Inc (NYSE:CRL)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/nordea-investment-management-ab-cuts-holdings-in-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: How does new data get added to a blockchain?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.